



ASX Announcement

9 July 2024

Appendix 3Y Cover Note

SYDNEY Australia, 9 July 2024 –Atomo Diagnostics Limited (ASX: AT1) (**Atomo** or the **Company**) makes this announcement in relation to the Appendix 3Y “Change of Director’s Interest Notice” lodged with the ASX today.

The Company advises the following in relation to the late lodgement of these documents:

- The Appendix 3Y was being lodged late due to an administrative oversight. As soon as the oversight was identified, the documents were prepared and lodged with the ASX.
- The Company and its Directors are aware of their obligations under Listing Rules 3.19A and 3.19B and have procedures in place in accordance with the Company’s Continuous Disclosure Policy to meet its disclosure obligations.
- The Company considers that the late lodgement is an isolated incident and believes its current practices are adequate to ensure compliance with the Listing Rules.

This announcement was authorised by the Board of Atomo Diagnostics Limited.

For more information:

John Kelly
MD & CEO
Atomo Diagnostics Limited
john.kelly@atomodiagnostics.com
+61 401 922 279

About Atomo

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo’s unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health.

See more at www.atomodiagnostics.com

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Atomo Diagnostics Limited
ABN	37 142 925 684

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	John Kelly
Date of last notice	9 August 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-	Mr Kelly is a controller of Dalraida Holdings Pty Ltd
Date of change	14 April 2024	N/A
No. of securities held prior to change	7,370,248 FPOs 999,999 Unquoted Options	65,120,000 FPOs
Class	Unquoted Options	N/A
Number acquired	Nil	N/A
Number disposed	333,333 Unquoted Options	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil	N/A
No. of securities held after change	7,370,248 FPOs 666,666 Unquoted Options	65,120,000 FPOs

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Expiry of option without exercise on 14 April 2024.	N/A
---	---	-----

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.